Experimental study of K562 cell apoptosis induced by siRNA.
- Author:
Bo-bin CHEN
1
;
Hua-hua FAN
;
Guo-wei LIN
;
Zheng-hong YUAN
;
Hua-zhong LU
;
Li GAO
;
Yan LIU
Author Information
- Publication Type:Journal Article
- MeSH: Apoptosis; Base Sequence; Flow Cytometry; Fusion Proteins, bcr-abl; genetics; Genetic Vectors; Humans; In Situ Nick-End Labeling; K562 Cells; Plasmids; genetics; RNA, Messenger; genetics; RNA, Small Interfering; genetics; Transfection
- From: Chinese Journal of Hematology 2004;25(12):717-719
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVESTo construct a siRNA expression vector pBCR6 that produces siRNA against bcr/abl mRNA and detect apoptosis rate of K562 cells after pBCR6 transfection.
METHODSTemplate sequence for siRNA was designed, synthesized and inserted into an expression vector pSilencer1.0-U6. Restriction analysis and sequencing were performed to verify the pBCR6 vector. Then pBCR6 was transfected into K562 cells by X-tremeGene Q2. pSilencer1.0-U6 was used as the control. At different time point after transfection, apoptosis rate was determined by Tunel and Annexin V+ PI with FCM.
RESULTpBCR6 was verified by restriction analysis and sequencing. The apoptosis rate of K562 cells markedly increased at 48 and 72 hour after transfected with pBCR6, and increased in a time-dependent manner [the apoptosis rate of transfected K562 cells was (47.80 +/- 1.63)% at 72 hrs, whereas the control group was (6.67 +/- 0.37)%, P < 0.0001] No prominent change in apoptosis rate was found in the control.
CONCLUSIONThe siRNA expression vector against bcr/abl mRNA was successfully constructed. The pilot study showed that pBCR6 could effectively induce K562 cells apoptosis. siRNA may be a new tool for molecular target therapy for chronic myelogenous leukemia.